REG - CRISM Therapeutics - Placing of £1,000,000

CRISM TherapeuticsAnnouncement

10/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251210:nRSJ9159Ka&default-theme=true

RNS Number : 9159K  CRISM Therapeutics Corporation  10 December 2025

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

10 December 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Placing of £1,000,000

 

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical stage company
focused on the localised and sustained delivery of chemotherapy drugs, is
pleased to announce that it has successfully raised £1,000,000 by way of an
oversubscribed placing of 11,111,112 new ordinary shares of no par value each
in the Company ("Placing Shares") at a price of 9 pence per share (the "Issue
Price") (the "Placing"). The Placing Shares each have an attaching grant of
warrants ("Warrants") on a one for two basis, exercisable at a price of 15
pence per ordinary share, and expiring on 31 December 2026.

 

The Placing Shares will represent approximately 21.76% of the Company's
enlarged issued share capital following the Placing. The Issue Price
represents a discount of approximately 18.18 per cent. to the closing
mid-market price of 9 pence per ordinary share on 09 December 2025.

 

The Placing was undertaken by the Company's broker, SP Angel Corporate Finance
LLP.

 

The Company values its retail shareholder base and believes that it is
appropriate to provide existing retail and other shareholders the opportunity
to purchase shares at the Issue Price.  The Company intends to carry out a
separate retail offer to raise further gross proceeds of up to £100,000 via
the BookBuild Platform (the "Retail Offer"). A further announcement will be
made shortly regarding the Retail Offer and its terms.

 

Highlights of the Placing:

 

-      Completion of Placing raising £1,000,000 through the issue of
11,111,112 Placing Shares at 9 pence per share

-      The net proceeds of the Placing will allow the Company to progress
its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in
patients with surgically resectable glioblastoma. Specifically, funds will be
used for:

o  Sterilisation and lot release of GMP of ChemoSeed

o  QP, quality and audit fees

o  Clinical trial costs - ongoing fees, dose escalation seeking efficacy
signal in recurrent patients

o  Ongoing operational costs

-      A separate retail offer to existing holders will be launched
shortly

 

CRISM Executive Chairman, Andrew Webb, said: "We are delighted by the support
of new and existing shareholders in this oversubscribed Placing, which will
enable the Company to progress into patient dosing in its Phase 2 clinical
trial of irinotecan-ChemoSeed in glioblastoma and to reach the important
inflexion point of establishing an efficacy signal in patients with recurrent
disease, subject to patient recruitment. We look forward to first patient
dosing in Q1 2026."

 

Rationale for the Placing

 

The Placing will enable the Company to progress its Phase 2 open-label
clinical trial, with first patients expected to be dosed in Q1 2026. The open
label trial design allows for ongoing safety and efficacy monitoring.

 

Directors' Participation and Related Party Transactions

 

The Directors of the Company have participated in the Placing, details of
which are in the table below:

 

 Director          Number of Placing Shares subscribed for  Number of ordinary shares held immediately following Admission  % interest in ordinary shares immediately following Admission
 Andrew Webb       916,667                                  7,297,190                                                       14.29%
 Chris McConville  83,333                                   4,992,033                                                       9.77%
 Gerry Beaney      111,111                                  268,793                                                         0.53%

 

The participation of Andrew Webb, Chris McConville and Gerry Beaney in the
Placing (including the issue of the Warrants referred to below) constitutes
related party transactions for the purposes of Rule 13 of the AIM Rules for
Companies. As all of the Directors are participating in the Placing, there is
no independent director for the purpose of the related party transaction as
stipulated by the AIM Rules for Companies.

 

The Company's nominated adviser, SP Angel Corporate Finance LLP, considers
that the Directors' participation in, and the terms of, the Placing is fair
and reasonable in so far as CRISM's shareholders are concerned.

 

Warrants

 

The Company will issue participants of the Placing with one Warrant for every
two Placing Shares. As a result, 5,555,551 Warrants will be issued to the
placees. Each Warrant will provide the holder with the right to one new
ordinary share on its exercise. The Warrants will be exercisable at a price of
15 pence until 31 December 2026.

 

Andrew Webb, Chris McConville and Gerry Beaney, have been issued with 458,333,
41,666 and 55,555 Warrants respectively, as a result of their participation in
the Placing.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for admission of the
Placing Shares ("Admission"). It is expected that Admission will become
effective and that trading will commence in the Placing Shares at 8.00 a.m. on
or around 15 December 2025, or such later date as may be agreed between the
Company and SP Angel. The Placing Shares will rank pari passu with the
Company's existing ordinary shares.

 

Following the issue of the Placing Shares, the total issued share capital of
the Company will consist of 51,072,934 ordinary shares. The Company does not
hold any ordinary shares in treasury. Therefore, the total number of voting
rights in the Company is 51,072,934 and this figure may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.

 

 

-Ends-

Enquiries:

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, Exec. Chair.       Richard Morrison (Corp Fin)       Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl (Corp Fin)              CRISM@buchanancomms.co.uk

                                 Vadim Alexandre (Sales)

                                 Rob Rees (Sales)
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

CRISM will initiate its registration-grade Phase 2 clinical
trial of irinotecan-ChemoSeed™ in patients with surgically resectable
glioblastoma in Q1 2026.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

  1   Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1)    Andrew Webb

                                                                   2)    Gerald Beaney

                                                                   3)    Chris McConville
 2    Reason for the notification

 a)   Position/status                                              1)    Executive Chairman

                                                                   2)    Non-Executive Director

                                                                   3)    Chief Scientific Officer
 b)   Initial notification /Amendment                               Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                          CRISM Therapeutics Corporation

 b)   LEI                                                          213800XFW6MKVCHHPW88

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares with no par value

      Identification code                                          ISIN: VGG042401262

 b)   Nature of the transaction                                    Purchase of shares

 c)   Price(s) and volume(s)

Director/PDMR     Price (£)   Volume

                                                                                     Andrew Webb       0.09        916,667

                 Gerald Beaney     0.09        111,111

                                                                                     Chris McConville  0.09        83,333

 d)   Aggregated information

      - Aggregated volume                                           N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      10 December 2025

 f)   Place of the transaction                                     Outside a trading venue

 

 

 

 

 

 

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A

- Price

N/A

e)

 

Date of the transaction

10 December 2025

f)

 

Place of the transaction

Outside a trading venue

 

 

  1   Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1)    Andrew Webb

                                                                   2)    Gerald Beaney

                                                                   3)    Chris McConville
 2    Reason for the notification

 a)   Position/status                                              1)    Executive Chairman

                                                                   2)    Non-Executive Director

                                                                   3)    Chief Scientific Officer
 b)   Initial notification /Amendment                               Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                          CRISM Therapeutics Corporation

 b)   LEI                                                          213800XFW6MKVCHHPW88

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares with no par value

      Identification code                                          ISIN: VGG042401262

 b)   Nature of the transaction                                    Issue of warrants

 c)   Price(s) and volume(s)

Director/PDMR     Exercise Price  Volume

                                                                                     Andrew Webb       £0.15           458,333

                 Gerald Beaney     £0.15           55,555

                                                                                     Chris McConville  £0.15           41,666

 d)   Aggregated information

      - Aggregated volume                                           N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      10 December 2025

 f)   Place of the transaction                                     Outside a trading venue

 

 

 

 

 

 

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A

- Price

N/A

e)

 

Date of the transaction

10 December 2025

f)

 

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAFANESESFAA



            Copyright 2019 Regulatory News Service, all rights reserved